Pacific Biosciences of California, Inc.
US ˙ NasdaqGS ˙ US69404D1081

SecurityPACB / Pacific Biosciences of California, Inc.
InsiderOene Mark Van
This page shows the track record and history of Van Oene Mark insider trades in Pacific Biosciences of California, Inc.. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company. It is illegal for insiders to make trades in their companies based on material, non-public information ("MNPI"). This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.
Insider Purchases - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made by Oene Mark Van in PACB / Pacific Biosciences of California, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PACB / Pacific Biosciences of California, Inc. Insider Trades
Insider Sales - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made by Oene Mark Van in PACB / Pacific Biosciences of California, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-08-18 26,836 1.3110 26,836 1.3110 35,182 25 1.1700 -3,783 -10.75
2025-03-03 6,486 1.4070 6,486 1.4070 9,126
2025-02-18 100,773 1.8780 100,773 1.8780 189,252
2025-01-10 34,405 2.0340 34,405 2.0340 69,980
2024-08-16 38,011 1.6620 38,011 1.6620 63,174
2024-03-04 9,186 4.8710 9,186 4.8710 44,745
2024-02-16 33,560 5.9580 33,560 5.9580 199,950
2024-01-09 31,012 7.7730 31,012 7.7730 241,056
2023-08-16 26,102 11.0000 26,102 11.0000 287,122
2023-03-03 6,268 9.4930 6,268 9.4930 59,502
2023-01-10 26,722 9.5340 26,722 9.5340 254,768
2022-01-11 41,480 14.2300 41,480 14.2300 590,260

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PACB / Pacific Biosciences of California, Inc. Insider Trades
Insider Transaction History
File
Date
Trade
Date
Form Insider Ticker Security Title Code 10b5-1 Direct Exercise
Price
Unit
Price
Units
Changed
Value
Changed (1K)
Remaining
Options
Remaining
Shares
2025-08-20 2025-08-18 4 Van Oene Mark PACB Common Stock S - Sale D 1.3110 -26,836 -35 1,920,035
2025-03-21 2025-03-19 4 Van Oene Mark PACB Common Stock A - Award D 449,176 1,946,871
2025-03-05 2025-03-03 4 Van Oene Mark PACB Common Stock S - Sale D 1.4070 -6,486 -9 1,497,695
2025-02-19 2025-02-18 4 Van Oene Mark PACB Common Stock S - Sale D 1.8780 -100,773 -189 1,496,681
2025-01-10 2025-01-10 4 Van Oene Mark PACB Common Stock S - Sale D 2.0340 -34,405 -70 1,597,454
2024-08-20 2024-08-16 4 Van Oene Mark PACB Common Stock S - Sale D 1.6620 -38,011 -63 1,630,815
2024-03-06 2024-03-04 4 Van Oene Mark PACB Common Stock S - Sale D 4.8710 -9,186 -45 1,668,826
2024-02-26 2024-02-22 4 Van Oene Mark PACB Common Stock A - Award D 798,076 1,674,687
2024-02-21 2024-02-16 4 Van Oene Mark PACB Common Stock S - Sale D 5.9580 -33,560 -200 876,611
2024-01-10 2024-01-09 4 Van Oene Mark PACB Common Stock S - Sale D 7.7730 -31,012 -241 910,171
2023-08-18 2023-08-16 4 Van Oene Mark PACB Common Stock S - Sale D 11.0000 -26,102 -287 939,769
2023-03-06 2023-03-03 4 Van Oene Mark PACB Common Stock S - Sale D 9.4930 -6,268 -60 965,871
2023-03-06 2023-03-02 4 Van Oene Mark PACB Common Stock A - Award D 328,500 972,139
2023-01-11 2023-01-10 4 Van Oene Mark PACB Common Stock S - Sale D 9.5340 -26,722 -255 640,808
2022-08-26 2022-08-25 4 Van Oene Mark PACB Common Stock A - Award D 300,000 667,528
2022-03-04 2022-03-02 4 Van Oene Mark PACB Stock Option (right to buy) A - Award D 11.70 433,200 433,200
2022-03-04 2022-03-02 4 Van Oene Mark PACB Common Stock A - Award D 72,500 366,020
2022-01-13 2022-01-11 4 Van Oene Mark PACB Common Stock S - Sale D 14.2300 -41,480 -590 293,520
2021-01-12 2021-01-08 4 Van Oene Mark PACB Stock Option (right to buy) A - Award D 36.70 750,000 750,000
2021-01-12 2021-01-08 4 Van Oene Mark PACB Common Stock A - Award D 335,000 335,000
P
Köp på öppna marknaden eller privat köp av icke-derivatsäkerhet
S
Köp på öppna marknaden eller privat försäljning av icke-derivatsäkerhet
A
Bevilja, tilldelning eller annat förvärv av värdepapper från företaget (såsom en option)
C
Omvandling av derivat
D
Försäljning eller överföring av värdepapper tillbaka til företaget
F
Betalning av lösenpris eller skatteskuld med del av värdepapper som erhållits från bolaget
G
Överlåtelse av värdepapper från eller till insidern
K
Aktieswappar och liknande säkringsaffärer
M
Utövande eller omvandling av derivatsäkerhet som erhållits från företaget (som en option)
V
En transaktion friviligt rapporterad på schema 4
J
Andra (med en fotnot som beskriver transaktionen)